SMS1-IN-1
Based on 1 Customer Validation
SMS1-IN-1, compound SAPA 1j, is a novel and the most potent sphingomyelin synthase 1 (SMS1) inhibitor with an IC50 value of 2.1 μM. SMS1-IN-1 has the potential for the treatment of atherosclerosis.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 98.38%
- CAS. Nr.: 1807943-38-9
- Formel: C23H23BrN2O4S
- Molecular Weight:503.41
-
Speicherung:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Protokoll
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Alle Phospholipase Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
Beschreibung
IC50 & Target
IC50: 2.1 μM (SMS1)[1]
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HeLa | IC50 |
2.1 μM
Compound: 1j
|
Inhibition of sphingomyelin synthase-1 (unknown origin) expressed in HeLa cells using C6-NBD-Cer and DMPC as substrate after 2 hrs by fluorescent HPLC-based analysis
Inhibition of sphingomyelin synthase-1 (unknown origin) expressed in HeLa cells using C6-NBD-Cer and DMPC as substrate after 2 hrs by fluorescent HPLC-based analysis
|
[PMID: 26314925] |
In Vitro
SMS1-IN-1 (2.5, 10 and 50 μM) has a dose-dependent inhibitory effect against SMS1, and is against SMS1 with an IC50 value of 2.1 μM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Chemical Information
-
CAS. Nr. 1807943-38-9
-
Appearance Solid
-
Molecular Weight 503.41
-
Formel C23H23BrN2O4S
-
Color Off-white to light brown
-
SMILES
O=C(NCC1=CC=C(Br)C=C1)COC2=CC=C(S(=O)(NCCC3=CC=CC=C3)=O)C=C2
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Lösungsmittel & Löslichkeit
In Vitro:
DMSO : 250 mg/mL (496.61 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Protokoll
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Research Protocol for Cardiovascular Diseases
Cardiovascular disease can be modeled as maladaptive cardiac remodeling, where ischemic injury or pressure overload activates inflammatory signaling, fibroblast activation, extracellular-matrix deposition, cardiomyocyte hypertrophy, vascular remodeling, and progressive ventricular dysfunction. The TGF-β/SMAD axis is a central profibrotic pathway after myocardial injury and pressure overload, while innate immune and cytokine pathways regulate leukocyte recruitment, scar formation, and adverse remodeling. Key unresolved questions include which inflammatory signals are reparative versus harmful, when fibrosis is protective versus maladaptive, and whether pathway inhibition improves function without weakening necessary infarct healing or compensatory remodeling.
Reinheit & Dokumentation
-
Data Sheet (268 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
Verweise
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.9865 mL | 9.9323 mL | 19.8645 mL | 49.6613 mL |
| 5 mM | 0.3973 mL | 1.9865 mL | 3.9729 mL | 9.9323 mL | |
| 10 mM | 0.1986 mL | 0.9932 mL | 1.9865 mL | 4.9661 mL | |
| 15 mM | 0.1324 mL | 0.6622 mL | 1.3243 mL | 3.3108 mL | |
| 20 mM | 0.0993 mL | 0.4966 mL | 0.9932 mL | 2.4831 mL | |
| 25 mM | 0.0795 mL | 0.3973 mL | 0.7946 mL | 1.9865 mL | |
| 30 mM | 0.0662 mL | 0.3311 mL | 0.6622 mL | 1.6554 mL | |
| 40 mM | 0.0497 mL | 0.2483 mL | 0.4966 mL | 1.2415 mL | |
| 50 mM | 0.0397 mL | 0.1986 mL | 0.3973 mL | 0.9932 mL | |
| 60 mM | 0.0331 mL | 0.1655 mL | 0.3311 mL | 0.8277 mL | |
| 80 mM | 0.0248 mL | 0.1242 mL | 0.2483 mL | 0.6208 mL | |
| 100 mM | 0.0199 mL | 0.0993 mL | 0.1986 mL | 0.4966 mL |
SMS1-IN-1 Related Classifications
HY-135642 Related Classifications
Powered by Bioz